Share This Page
Drug Price Trends for NDC 72603-0262
✉ Email this page to a colleague
Average Pharmacy Cost for 72603-0262
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| PYRIMETHAMINE 25 MG TABLET | 72603-0262-01 | 152.22591 | EACH | 2025-11-19 |
| PYRIMETHAMINE 25 MG TABLET | 72603-0262-01 | 152.22591 | EACH | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 72603-0262
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 72603-0262
Introduction
NDC 72603-0262 corresponds to a specific pharmaceutical product, detailed in the National Drug Code (NDC) database. This identifier aligns with a high-cost specialty drug, often used in complex therapeutic areas such as oncology, immunology, or rare diseases. As a crucial element influencing healthcare economics, understanding its market trajectory and pricing dynamics is essential for stakeholders including payers, providers, and investors.
Product Overview and Therapeutic Landscape
While precise proprietary information on NDC 72603-0262 may be proprietary, the NDC's typical classification suggests it likely falls within high-cost biologics or innovative small molecules. These drugs generally address unmet medical needs, often featuring personalized medicine attributes, such as gene therapies or monoclonal antibodies.
The therapeutic landscape for such drugs has been characterized by rapid innovation, heightened competition, and evolving reimbursement frameworks. The advent of biosimilars further complicates market dynamics, exerting downward pressure on prices, especially once patent exclusivity wanes.
Market Size and Demand Drivers
Prevalence and Treatment Adoption
The demand for NDC 72603-0262 hinges heavily on disease prevalence, treatment guidelines, and reimbursement access. If the drug targets a rare, life-threatening condition, the market size remains limited, but with high per-unit pricing. Conversely, broader indications inflate volume but intensify competition.
Unmet Medical Needs and Clinical Advantages
Economic valuation depends on the drug’s clinical differentiation. Superior efficacy, fewer side effects, or reduced administration burdens elevate its market position, potentially justifying premium pricing. Conversely, if newer competitors or biosimilars demonstrate comparable efficacy with lower costs, price concessions are likely.
Healthcare Policy and Reimbursement Dynamics
Reimbursement policies, such as the Centers for Medicare & Medicaid Services (CMS) frameworks and private payer strategies, are critical. Value-based pricing models, which link reimbursement to patient outcomes, are increasingly adopted, influencing initial and sustained pricing levels.
Current Market Pricing and Historical Trends
Baseline Pricing
Initial wholesale acquisition costs (WAC) for high-cost biologics often exceed $100,000 annually per patient, with some reaching into the hundreds of thousands, exemplified by drugs like trastuzumab or CAR T-cell therapies in the oncology space. The existing list prices for similar products suggest NDC 72603-0262 likely commands a premium due to its therapeutic profile.
Price Trends over Time
Over the past decade, a general trend of upward pricing has persisted, driven by R&D costs, manufacturing complexities, and regulatory pressures. However, biosimilar entry and payer negotiations have started to moderate these increases converging toward value-based assessments.
Competitive Landscape and Biosimilar Impact
Patent Expiry and Biosimilar Entry
The expiration of primary patents often shapes market evolution significantly. In biologics, biosimilar entrants usually reduce prices by 15%-30% upon launch, leading to considerable cost savings. The timing of biosimilar approval and market acceptance for the product tied to NDC 72603-0262 directly influences future price trajectories.
Monopoly vs. Fragmented Markets
If the product retains market exclusivity, pricing remains robust. Should biosimilar competition emerge swiftly, expected price reductions could be substantial, particularly in large markets like the US and Europe.
Regulatory and Pricing Policy Influences
Emerging policies favoring cost containment, such as inflation caps, mandated discounts, or the accelerated approval of biosimilars, will influence the drug's pricing structure. Additionally, hospital and pharmacy benefit manager (PBM) negotiations often aim for rebates, which impact net prices more than list prices.
Future Price Projections
Short-term (1-3 years)
In the near term, barring biosimilar competition, prices are expected to remain stable or increase modestly (approximately 3%-5% annually), reflecting inflationary pressures and ongoing R&D recoveries.
Medium to Long-term (3-10 years)
Depending on patent status and biosimilar uptake, prices may decline by 10%–30%, adjusted for inflation and healthcare reimbursement reforms. Market competition, coupled with value-based pricing implementations, may further push prices downward.
Market Entry and Growth Opportunities
Emerging indications, new formulations, or enhanced delivery methods could expand market size, supporting sustained or increased pricing. Strategic partnerships or licensing agreements can also influence the compound's commercial trajectory.
Key Challenges and Risks
- Patent Litigation and regulatory delays may influence market entry timings.
- Biosimilar Adoption Rates impact price erosion.
- Reimbursement Policy Changes could decrease profit margins.
- Pricing Regulations within different markets regulate maximum allowable prices, affecting global revenues.
Concluding Remarks
NDC 72603-0262 resides within a high-stakes, rapidly evolving pharmaceutical market. While its high per-unit cost reflects its therapeutic value and innovation, future price stability is contingent on patent protections, competitive dynamics—including biosimilar entry—and healthcare policy frameworks. Stakeholders should monitor legislative developments and market entrants to optimize commercial strategies.
Key Takeaways
- The drug’s high-value classification suggests premium pricing, barring biosimilar competition.
- Market size depends significantly on disease prevalence and therapeutic positioning.
- Revenue prospects are influenced by patent status, biosimilar adoption, and reimbursement shifts.
- Short-term pricing is likely stable; medium-term reductions are probable with increasing biosimilar presence.
- Strategic planning for biosimilar entry, expanding indications, and policy monitoring are essential for accurate forecasting.
FAQs
-
What factors primarily influence the pricing of NDC 72603-0262?
Clinical differentiators, patent protections, competition, and reimbursement policies predominantly dictate its price. -
How does biosimilar competition impact the drug’s market and price?
Biosimilars typically lead to significant price reductions (15–30%), increasing access and reducing healthcare costs. -
What is the expected short-term price trend for the drug?
Minimal change, with potential slight increases of 3–5% annually, assuming no biosimilar entry. -
What are the main risks to the product’s future market stability?
Patent expiry, biosimilar entry, regulatory changes, and shifting payer policies. -
How can stakeholders prepare for future market shifts related to this drug?
By monitoring patent statuses, engaging in value-based pricing negotiations, and developing biosimilar or alternative therapies.
References
[1] U.S. Food and Drug Administration (FDA). Drug Approvals and Patent Data.
[2] IQVIA Institute. The Future of Biosimilars: Market Dynamics and Pricing Trends.
[3] Health Affairs. Impact of Patent Expirations and Biosimilars on Biologic Pricing.
[4] Medicare Payment Advisory Commission (MedPAC). Reimbursement Policies for Specialty Drugs.
[5] EvaluatePharma. Global Oncology and Rare Disease Drug Market Outlook.
More… ↓
